熱門資訊> 正文
Axsome Therapeutics达成协议，驳回与Sandoz的专利诉讼
2024-08-21 19:51
- Axsome Therapeutics (NASDAQ:AXSM) has reached an agreement with Sandoz (OTCQX:SDZNY) to dismiss the patent litigation related to Axsome’s product Sunosi (solriamfetol), it said on Wednesday.
- The litigation, which was pending in the United States District Court for the District of New Jersey, resulted from submission by Sandoz of an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market a generic equivalent of Sunosi in the United States.
- Sandoz (OTCQX:SDZNY) withdrew its ANDA for a generic equivalent of Sunosi, and, as a result, the litigation has been dismissed without prejudice.
- Source: Press Release
More on Axsome Therapeutics, Sandoz Group AG, etc.
- Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)
- BofA upgrades Axsome to buy, cites upcoming Auvelity data
- Axsome Therapeutics GAAP EPS of -$1.67 misses by $0.34, revenue of $87.2M beats by $0.27M
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
